Ipsen expands early development pipeline with Simcere Zaiming's innovative antibody drug conjugate

Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate
SIM0613 is optimally designed for superior tumor penetration with robust preclinical efficacy data
Program expected to enter Phase I clinical development in H2 2026
Simcere Zaiming is eligible to receive up to $1.06B in total payments

PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen ((Euronext: IPN, OTC:IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC15 protein, SIM0613 is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest